tradingkey.logo
tradingkey.logo
Suchen

Daxor Corp

DXR
Zur Watchlist hinzufügen
11.020USD
+0.670+6.47%
Trading geöffnet ETKurse um 15 Minuten verzögert
55.76MMarktkapitalisierung
31.69KGV TTM

mehr Informationen über Daxor Corp Unternehmen

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Daxor Corp Informationen

BörsenkürzelDXR
Name des UnternehmensDaxor Corp
IPO-datumJul 25, 1983
CEOFeldschuh (Michael Richard)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJul 25
AddresseSuite 7120
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10118
Telefon12122440555
Websitehttps://www.daxor.com/
BörsenkürzelDXR
IPO-datumJul 25, 1983
CEOFeldschuh (Michael Richard)

Führungskräfte von Daxor Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
--
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
--
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
--
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
--
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Daxor Corp?

Die fünf größten Anteilseigner von Daxor Corp sind: Mr. Michael Richard Feldschuh

Wie viele Institutionen halten Anteile an Daxor Corp (DXR)?

Mit Stand vom 2026Q1 halten 16 Institutionen Anteile an Daxor Corp, mit einem Gesamtmarktwert von etwa 120.43K, was 2.07% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 11270.00 gestiegen.